fbpx
 

Financials

Patti-Headshot

At The Max Foundation, we have a deep commitment to good stewardship of every donated dollar and contributed medicines. We look forward to increasing our impact on behalf of patients everywhere.”

—Patricia M. Pearce, CPA, CGMA, Chief Financial Officer & VP, Administration

2017 Financials

2017 Revenue Amount Percentage
Gifts-In-Kind · Pharmaceuticals $190,595,434 96.6%
Corporate Services Agreements $1,070,985 0.5%
Contributions, Grants & Sponsorships $5,386,877 2.7%
Diagnostic Program Revenue $312,689 0.2%
Other Income $9,127 0%
 Total $197,375,112 100.0%
2017 Expenses Amount Percentage
Program Services Expense $54,727,479 97.8%
Management & General $742,814 1.3%
Fundraising $482,926 0.9%
Total $55,953,219 100%

The planned transition of the Glivec International Patient Assistance Program program to CMLPath to CareTM under the umbrella of the Max Access Solutions model, launched in July of 2017, required the organization to stock up its inventory to ensure a continuous supply of medicines to patients in the program.

While 50 out of the 67 countries to be transitioned did so in 2017, at year end, the organization was holding a substantial volume of inventory on hand while we sought import permits and other necessary regulatory documentation for distribution at the different sites.

Valuation of Gifts-In-Kind

Prior to 2017, The Max Foundation’s fair value of donated pharmaceuticals was based on prices from Thomas Reuters Red Book Actual Wholesale Price (AWP). During 2017, The Max Foundation obtained fair value data from a third-party source which reflects wholesale prices available in multiple relevant international markets. The gifts-in-kind are recorded, by drug, based on the estimated fair value in the relevant international market of highest volume.

Previous Financials

The Max Foundation is committed to transparency, ethical accounting, and donor stewardship. The Max Foundation is a US registered 501(c)(3) non-profit organization. Donations to The Max Foundation are tax-deductible to the extent permitted by the law. Our fiscal year runs January through December and we post our audited financials and annual report during the summer of the following year.

Follow the Patient Journey

Join Rosario as she shares her journey from cancer patient to advocate and leader.
See Rosario's Journey
r01_rosario